Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. / Åkeson, Per; Jonsson, E; Haugen, I; Holtås, Stig.

I: Neuroradiology, Vol. 37, Nr. 3, 1995, s. 229-233.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Åkeson, Per ; Jonsson, E ; Haugen, I ; Holtås, Stig. / Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. I: Neuroradiology. 1995 ; Vol. 37, Nr. 3. s. 229-233.

RIS

TY - JOUR

T1 - Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA

AU - Åkeson, Per

AU - Jonsson, E

AU - Haugen, I

AU - Holtås, Stig

PY - 1995

Y1 - 1995

N2 - Gadodiamide injection, a new nonionic, MRI contrast medium, was compared with the ionic agent gadolinium (Gd)-DTPA at 0.1 mmol/kg body weight in a double-blind, randomised trial in 60 patients, 30 receiving each substance, with known or suspected lesions of the central nervous system. The patients were closely questioned about adverse events. In the Gadodiamide injection group, four patients reported six adverse advents, three of which were judged to be related to the contrast medium. In the Gd-DTPA group, two patients each reported one adverse event, both of which had an uncertain relation to the contrast medium. All events were mild and no medical treatment was needed. No significant change in neurological findings, blood pressure, pulse rate or blood parameters were noted in any patient. Both contrast media were effective; no difference in overall efficacy or safety was observed.

AB - Gadodiamide injection, a new nonionic, MRI contrast medium, was compared with the ionic agent gadolinium (Gd)-DTPA at 0.1 mmol/kg body weight in a double-blind, randomised trial in 60 patients, 30 receiving each substance, with known or suspected lesions of the central nervous system. The patients were closely questioned about adverse events. In the Gadodiamide injection group, four patients reported six adverse advents, three of which were judged to be related to the contrast medium. In the Gd-DTPA group, two patients each reported one adverse event, both of which had an uncertain relation to the contrast medium. All events were mild and no medical treatment was needed. No significant change in neurological findings, blood pressure, pulse rate or blood parameters were noted in any patient. Both contrast media were effective; no difference in overall efficacy or safety was observed.

KW - Brain

KW - MRI · Spine

KW - MRI · Gadolinium contrast media

U2 - 10.1007/BF01578263

DO - 10.1007/BF01578263

M3 - Article

VL - 37

SP - 229

EP - 233

JO - Neuroradiology

JF - Neuroradiology

SN - 1432-1920

IS - 3

ER -